ID   NR2C1_MOUSE             Reviewed;         590 AA.
AC   Q505F1; P97763; Q0VGP8; Q3UIJ7; Q4U1Z4; Q60927; Q62152; Q8VIJ3;
DT   06-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   07-APR-2021, entry version 142.
DE   RecName: Full=Nuclear receptor subfamily 2 group C member 1;
DE   AltName: Full=Orphan nuclear receptor TR2;
DE   AltName: Full=Testicular receptor 2;
DE            Short=mTR2;
GN   Name=Nr2c1 {ECO:0000312|MGI:MGI:1352465};
GN   Synonyms=Tr2, Tr2-11 {ECO:0000312|EMBL:AAC53253.1};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC53253.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, DEVELOPMENTAL STAGE,
RP   AND VARIANTS MET-29; MET-145; 296-SER--LYS-304; ILE-361; ALA-377 AND
RP   ALA-456.
RC   STRAIN=CD-1 {ECO:0000312|EMBL:AAC53253.1};
RC   TISSUE=Embryo {ECO:0000269|PubMed:8595902};
RX   PubMed=8595902; DOI=10.1006/geno.1995.0007;
RA   Lee C.-H., Copeland N.G., Gilbert D.J., Jenkins N.A., Wei L.-N.;
RT   "Genomic structure, promoter identification, and chromosomal mapping of a
RT   mouse nuclear orphan receptor expressed in embryos and adult testes.";
RL   Genomics 30:46-52(1995).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAC52787.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   DEVELOPMENTAL STAGE, AND VARIANTS MET-29; MET-145; 296-SER--LYS-304;
RP   ILE-361; ALA-377 AND ALA-456.
RC   STRAIN=CD-1 {ECO:0000312|EMBL:AAC52787.1};
RC   TISSUE=Embryo {ECO:0000269|PubMed:8858600};
RX   PubMed=8858600;
RX   DOI=10.1002/(sici)1098-2795(199607)44:3<305::aid-mrd4>3.0.co;2-q;
RA   Lee C.-H., Chang L., Wei L.N.;
RT   "Molecular cloning and characterization of a mouse nuclear orphan receptor
RT   expressed in embryos and testes.";
RL   Mol. Reprod. Dev. 44:305-314(1996).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=9071982; DOI=10.1677/joe.0.1520245;
RA   Lee C.-H., Chang L., Wei L.-N.;
RT   "Distinct expression patterns and biological activities of two isoforms of
RT   the mouse orphan receptor TR2.";
RL   J. Endocrinol. 152:245-255(1997).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:CAA72244.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   STRAIN=C3H X 102 {ECO:0000269|PubMed:9504722};
RX   PubMed=9504722;
RA   Immervoll T., Adamski J., Graw J.;
RT   "Polymorphism in the murine Tr2-11 gene encoding an orphan receptor, and
RT   its exclusion as a candidate gene for the cataract mutation Cat3.";
RL   Biol. Chem. 379:83-85(1998).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:AAC29502.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INDUCTION.
RC   STRAIN=C57BL/6J {ECO:0000312|EMBL:AAC29502.1};
RC   TISSUE=Testis {ECO:0000312|EMBL:AAC29502.1};
RX   PubMed=9694834; DOI=10.1074/jbc.273.33.20877;
RA   Young W.-J., Lee Y.-F., Smith S.M., Chang C.;
RT   "A bidirectional regulation between the TR2/TR4 orphan receptors (TR2/TR4)
RT   and the ciliary neurotrophic factor (CNTF) signaling pathway.";
RL   J. Biol. Chem. 273:20877-20885(1998).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAL31315.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RA   Ideta R., Yeh S., Lee Y.-F., Adachi K., Takeda H., Su C., Chang C.;
RT   "Cloning, antibody production and immunohistochemical localization of an
RT   androgen repressed of mouse and rat TR2 orphan receptors: a member of
RT   steroid receptor superfamily.";
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7] {ECO:0000305, ECO:0000312|EMBL:BAE28842.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J {ECO:0000312|EMBL:BAE28842.1};
RC   TISSUE=Embryonic kidney {ECO:0000269|PubMed:16141072}, and
RC   Liver tumor {ECO:0000312|EMBL:BAE28842.1};
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [9] {ECO:0000305, ECO:0000312|EMBL:AAH94580.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J {ECO:0000312|EMBL:AAH94580.1};
RC   TISSUE=Eye {ECO:0000312|EMBL:AAH94580.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   DNA-BINDING, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=8530418; DOI=10.1074/jbc.270.50.29636;
RA   Lin T.M., Young W.J., Chang C.;
RT   "Multiple functions of the TR2-11 orphan receptor in modulating activation
RT   of two key cis-acting elements involved in the retinoic acid signal
RT   transduction system.";
RL   J. Biol. Chem. 270:30121-30128(1995).
RN   [11] {ECO:0000305}
RP   DNA-BINDING, AND HOMODIMERIZATION.
RX   PubMed=9369481; DOI=10.1021/bi971598z;
RA   Chinpaisal C., Chang L., Hu X., Lee C.-H., Wen W.-N., Wei L.-N.;
RT   "The orphan nuclear receptor TR2 suppresses a DR4 hormone response element
RT   of the mouse CRABP-I gene promoter.";
RL   Biochemistry 36:14088-14095(1997).
RN   [12] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NRIP1.
RX   PubMed=9774688; DOI=10.1128/mcb.18.11.6745;
RA   Lee C.-H., Chinpaisal C., Wei L.-N.;
RT   "Cloning and characterization of mouse RIP140, a corepressor for nuclear
RT   orphan receptor TR2.";
RL   Mol. Cell. Biol. 18:6745-6755(1998).
RN   [13] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH HDAC3 AND HDAC4.
RX   PubMed=11463856; DOI=10.1210/mend.15.8.0682;
RA   Franco P.J., Farooqui M., Seto E., Wei L.-N.;
RT   "The orphan nuclear receptor TR2 interacts directly with both class I and
RT   class II histone deacetylases.";
RL   Mol. Endocrinol. 15:1318-1328(2001).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY IN DRED COMPLEX, FUNCTION, SUBCELLULAR
RP   LOCATION, HETERODIMERIZATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=12093744; DOI=10.1093/emboj/cdf340;
RA   Tanabe O., Katsuoka F., Campbell A.D., Song W., Yamamoto M., Tanimoto K.,
RA   Engel J.D.;
RT   "An embryonic/fetal beta-type globin gene repressor contains a nuclear
RT   receptor TR2/TR4 heterodimer.";
RL   EMBO J. 21:3434-3442(2002).
RN   [15]
RP   DISRUPTION PHENOTYPE, AND TISSUE SPECIFICITY.
RX   PubMed=12052874; DOI=10.1128/mcb.22.13.4661-4666.2002;
RA   Shyr C.R., Collins L.L., Mu X.M., Platt K.A., Chang C.;
RT   "Spermatogenesis and testis development are normal in mice lacking
RT   testicular orphan nuclear receptor 2.";
RL   Mol. Cell. Biol. 22:4661-4666(2002).
RN   [16]
RP   PHOSPHORYLATION AT SER-461 AND SER-568, FUNCTION, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=16130175; DOI=10.1002/pmic.200402062;
RA   Khan S.A., Park S.W., Huq M., Wei L.N.;
RT   "Protein kinase C-mediated phosphorylation of orphan nuclear receptor TR2:
RT   effects on receptor stability and activity.";
RL   Proteomics 5:3885-3894(2005).
RN   [17]
RP   PHOSPHORYLATION AT SER-185, DNA-BINDING, FUNCTION, INTERACTION WITH KAT2B,
RP   AND MUTAGENESIS OF SER-170 AND SER-185.
RX   PubMed=16317770; DOI=10.1002/pmic.200500068;
RA   Khan S.A., Park S.W., Huq M.D., Wei L.N.;
RT   "Ligand-independent orphan receptor TR2 activation by phosphorylation at
RT   the DNA-binding domain.";
RL   Proteomics 6:123-130(2006).
RN   [18]
RP   FUNCTION, AND HETERODIMERIZATION.
RX   PubMed=17431400; DOI=10.1038/sj.emboj.7601676;
RA   Tanabe O., McPhee D., Kobayashi S., Shen Y., Brandt W., Jiang X.,
RA   Campbell A.D., Chen Y.T., Chang C., Yamamoto M., Tanimoto K., Engel J.D.;
RT   "Embryonic and fetal beta-globin gene repression by the orphan nuclear
RT   receptors, TR2 and TR4.";
RL   EMBO J. 26:2295-2306(2007).
RN   [19]
RP   HETERODIMERIZATION, AND FUNCTION.
RX   PubMed=17974920; DOI=10.1101/gad.1593307;
RA   Tanabe O., Shen Y., Liu Q., Campbell A.D., Kuroha T., Yamamoto M.,
RA   Engel J.D.;
RT   "The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription.";
RL   Genes Dev. 21:2832-2844(2007).
RN   [20]
RP   SUMOYLATION AT LYS-238, SUBCELLULAR LOCATION, FUNCTION, INTERACTION WITH
RP   KAT2B; NRIP1; PIAS1 AND UBE2I, AND MUTAGENESIS OF LYS-167; LYS-238; GLU-240
RP   AND LYS-575.
RX   PubMed=17187077; DOI=10.1038/nsmb1185;
RA   Park S.W., Hu X., Gupta P., Lin Y.P., Ha S.G., Wei L.N.;
RT   "SUMOylation of Tr2 orphan receptor involves Pml and fine-tunes Oct4
RT   expression in stem cells.";
RL   Nat. Struct. Mol. Biol. 14:68-75(2007).
RN   [21]
RP   FUNCTION.
RX   PubMed=17389641; DOI=10.1093/nar/gkl1147;
RA   Gupta P., Park S.W., Farooqui M., Wei L.N.;
RT   "Orphan nuclear receptor TR2, a mediator of preadipocyte proliferation, is
RT   differentially regulated by RA through exchange of coactivator PCAF with
RT   corepressor RIP140 on a platform molecule GRIP1.";
RL   Nucleic Acids Res. 35:2269-2282(2007).
RN   [22]
RP   PHOSPHORYLATION AT SER-203; THR-208 AND THR-210, SUMOYLATION, INTERACTION
RP   WITH KAT2B, MUTAGENESIS OF SER-170; SER-185; SER-203; THR-208; THR-210;
RP   LYS-238; SER-461 AND SER-568, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18682553; DOI=10.1073/pnas.0710561105;
RA   Gupta P., Ho P.C., Huq M.M., Ha S.G., Park S.W., Khan A.A., Tsai N.P.,
RA   Wei L.N.;
RT   "Retinoic acid-stimulated sequential phosphorylation, PML recruitment, and
RT   SUMOylation of nuclear receptor TR2 to suppress Oct4 expression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:11424-11429(2008).
RN   [23]
RP   DISRUPTION PHENOTYPE, INDUCTION, AND FUNCTION.
RX   PubMed=19131575; DOI=10.1210/en.2008-1165;
RA   Shyr C.R., Kang H.Y., Tsai M.Y., Liu N.C., Ku P.Y., Huang K.E., Chang C.;
RT   "Roles of testicular orphan nuclear receptors 2 and 4 in early embryonic
RT   development and embryonic stem cells.";
RL   Endocrinology 150:2454-2462(2009).
RN   [24]
RP   SUMOYLATION, INTERACTION WITH HDAC3, AND SUBCELLULAR LOCATION.
RX   PubMed=19204783; DOI=10.1371/journal.pone.0004363;
RA   Gupta P., Ho P.C., Ha S.G., Lin Y.W., Wei L.N.;
RT   "HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a
RT   novel deacetylase activity-independent function of HDAC3.";
RL   PLoS ONE 4:E4363-E4363(2009).
CC   -!- FUNCTION: Orphan nuclear receptor. Binds the IR7 element in the
CC       promoter of its own gene in an autoregulatory negative feedback
CC       mechanism. Primarily repressor of a broad range of genes including ESR1
CC       and RARB. Together with NR2C2, forms the core of the DRED (direct
CC       repeat erythroid-definitive) complex that represses embryonic and fetal
CC       globin transcription. Binds to hormone response elements (HREs)
CC       consisting of two 5'-AGGTCA-3' half site direct repeat consensus
CC       sequences (By similarity). Also activator of OCT4 gene expression.
CC       Plays a fundamental role in early embryogenesis and regulates embryonic
CC       stem cell proliferation and differentiation. Mediator of retinoic acid-
CC       regulated preadipocyte proliferation. {ECO:0000250,
CC       ECO:0000269|PubMed:11463856, ECO:0000269|PubMed:12093744,
CC       ECO:0000269|PubMed:16130175, ECO:0000269|PubMed:16317770,
CC       ECO:0000269|PubMed:17187077, ECO:0000269|PubMed:17389641,
CC       ECO:0000269|PubMed:17431400, ECO:0000269|PubMed:17974920,
CC       ECO:0000269|PubMed:19131575, ECO:0000269|PubMed:8530418,
CC       ECO:0000269|PubMed:8858600, ECO:0000269|PubMed:9071982,
CC       ECO:0000269|PubMed:9774688}.
CC   -!- SUBUNIT: Homodimer. Heterodimer; with NR2C2 which is required for
CC       chromatin remodeling and for binding to promoter regions such as globin
CC       DR1 repeats. Interacts with ESR1; the interaction prevents
CC       homodimerization of ESR1 and suppresses its transcriptional activity
CC       and cell growth (By similarity). Interacts with NRIP1 (via its LXXLL
CC       motifs); the interaction provides corepressor activity. Interacts with
CC       HDAC3 (via the DNA-binding domain); the interaction recruits
CC       phosphorylated NR2C1 to PML bodies for sumoylation. Interacts with
CC       HDAC4 (via the DNA-binding domain). Interacts with PIAS1; the
CC       interaction is required for sumoylation of NR2C1. Interacts with UBE2I;
CC       the interaction is required for sumoylation of NR2C1. Interacts with
CC       KAT2B; the interaction acts as a corepressor of gene expression.
CC       {ECO:0000250, ECO:0000269|PubMed:11463856, ECO:0000269|PubMed:16317770,
CC       ECO:0000269|PubMed:17187077, ECO:0000269|PubMed:18682553,
CC       ECO:0000269|PubMed:19204783, ECO:0000269|PubMed:9774688}.
CC   -!- INTERACTION:
CC       Q505F1; Q9JHD1: Kat2b; NbExp=3; IntAct=EBI-15617004, EBI-2325611;
CC       Q505F1; Q8CBD1: Nrip1; NbExp=3; IntAct=EBI-15617004, EBI-1771626;
CC       Q505F1; O88907: Pias1; NbExp=4; IntAct=EBI-15617004, EBI-3508327;
CC       Q505F1; Q60953: Pml; NbExp=2; IntAct=EBI-15617004, EBI-3895605;
CC       Q505F1; Q8BSJ6: Pml; NbExp=3; IntAct=EBI-15617004, EBI-15719975;
CC       Q505F1; P63166: Sumo1; NbExp=5; IntAct=EBI-15617004, EBI-80152;
CC       Q505F1; P63280: Ube2i; NbExp=3; IntAct=EBI-15617004, EBI-80180;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, PML body. Note=Recruited by
CC       HDAC3, after all-trans retinoic acid stimulated MAPK1-mediated Thr-210
CC       phosphorylation, to PML bodies for subsequent sumoylation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1 {ECO:0000269|PubMed:8858600, ECO:0000269|PubMed:9504722,
CC       ECO:0000269|PubMed:9694834};
CC         IsoId=Q505F1-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:9071982}; Synonyms=TR2-11-t
CC       {ECO:0000303|PubMed:9071982}, TR2-11-truncated
CC       {ECO:0000303|PubMed:9071982};
CC         IsoId=Q505F1-2; Sequence=VSP_051921, VSP_051922;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is highly expressed in the adlumenal
CC       compartment of the seminiferous tubule of adult testes (at protein
CC       level) and in the eyes of newborn animals. Weakly expressed in other
CC       adult organs including the seminal vesicle, prostate, ovary, adrenal
CC       gland, heart, thymus, placenta and brain. Expressed during embryonic
CC       stages in developing eyes, brain and cartilage primordia (at protein
CC       level). Also expressed in the developing spinal motor neurons and in
CC       the sympathetic-, parasympathetic- and sensory ganglia of the embryonic
CC       PNS. Expressed in the developing neural epithelia of the inner ear,
CC       nasal cavity, tongue and retina. At day 16.5, expressed in various
CC       tissues including kidney and intestine. In contrast, isoform 2 is
CC       widely expressed at a low level throughout the adult testis.
CC       {ECO:0000269|PubMed:12052874, ECO:0000269|PubMed:8530418,
CC       ECO:0000269|PubMed:8595902, ECO:0000269|PubMed:8858600,
CC       ECO:0000269|PubMed:9071982, ECO:0000269|PubMed:9504722,
CC       ECO:0000269|PubMed:9694834}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 1 is highly expressed in early to
CC       midgestation embryos, with expression leveling off at 15 dpc. Expressed
CC       in yolk sac erythrocytes at 9.5 dpc. After birth, expression in the
CC       testes remains at a basal level until puberty, begins to increase at
CC       postnatal day 16 (P16) and peaks at P20 to P24. Expression is
CC       maintained at a high level throughout adulthood. Isoform 2 peaks
CC       transiently at P24. {ECO:0000269|PubMed:12093744,
CC       ECO:0000269|PubMed:8595902, ECO:0000269|PubMed:8858600,
CC       ECO:0000269|PubMed:9071982}.
CC   -!- INDUCTION: By ciliary neurotrophic factor (CNTF). Repressed by vitamin
CC       A. Induced by retinoic acid. {ECO:0000269|PubMed:19131575,
CC       ECO:0000269|PubMed:9694834}.
CC   -!- PTM: Sumoylation requires both PIAS1 and UBE2I. Sumoylation appears to
CC       dissociate NR2C1 from the PML nuclear bodies. Enhances the interaction
CC       with NRIP1 but inhibits interaction with KAT2B. In proliferating cells,
CC       stimulation by all-trans retinoic acid, activation of MAPK1-mediated
CC       phosphorylation and recruitment to PML bodies with subsequent
CC       sumoylation, suppresses OCT4 expression.
CC   -!- PTM: Phosphorylated on several serine and threonine residues.
CC       Phosphorylation on Thr-210, stimulated by all-trans retinoic acid
CC       (atRA) mediates PML location and sumoylation in proliferating cells
CC       which then modulates its association with effector molecules, KAT2B and
CC       NRIP1. Phosphorylation on Ser-568 by PKC is important for protein
CC       stability and function as activator of RARB.
CC       {ECO:0000269|PubMed:16130175, ECO:0000269|PubMed:18682553}.
CC   -!- DISRUPTION PHENOTYPE: No visible phenotype. Mice exhibit normal
CC       spermatogenesis and testis development, as well as normal central
CC       nervous system development. NR2C1 and NR2C2 double null mutants result
CC       in early embryonic lethality and increased apoptosis. Embryos die
CC       around 7.5 dpc. {ECO:0000269|PubMed:12052874,
CC       ECO:0000269|PubMed:19131575}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Due to intron retention.
CC       {ECO:0000303|PubMed:9071982}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR2
CC       subfamily. {ECO:0000255}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U28280; AAC53253.1; -; Genomic_DNA.
DR   EMBL; U28269; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28270; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28271; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28272; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28273; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28274; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28275; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28276; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28277; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28278; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28279; AAC53253.1; JOINED; Genomic_DNA.
DR   EMBL; U28265; AAC52787.1; -; mRNA.
DR   EMBL; Y11436; CAA72244.1; -; mRNA.
DR   EMBL; U30482; AAC29502.1; -; mRNA.
DR   EMBL; L26957; AAL31315.1; -; mRNA.
DR   EMBL; AK146891; BAE27509.1; -; mRNA.
DR   EMBL; AK149374; BAE28842.1; -; mRNA.
DR   EMBL; AC127596; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC138026; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC090662; AAH90662.1; -; mRNA.
DR   EMBL; BC094580; AAH94580.1; -; mRNA.
DR   CCDS; CCDS24131.1; -. [Q505F1-1]
DR   RefSeq; NP_035759.3; NM_011629.3. [Q505F1-1]
DR   RefSeq; XP_006513655.1; XM_006513592.2. [Q505F1-1]
DR   BioGRID; 204299; 2.
DR   DIP; DIP-29275N; -.
DR   IntAct; Q505F1; 7.
DR   STRING; 10090.ENSMUSP00000100927; -.
DR   iPTMnet; Q505F1; -.
DR   PhosphoSitePlus; Q505F1; -.
DR   EPD; Q505F1; -.
DR   jPOST; Q505F1; -.
DR   PaxDb; Q505F1; -.
DR   PeptideAtlas; Q505F1; -.
DR   PRIDE; Q505F1; -.
DR   ProteomicsDB; 293719; -. [Q505F1-1]
DR   ProteomicsDB; 293720; -. [Q505F1-2]
DR   Antibodypedia; 4166; 414 antibodies.
DR   Ensembl; ENSMUST00000092213; ENSMUSP00000089858; ENSMUSG00000005897. [Q505F1-1]
DR   Ensembl; ENSMUST00000099343; ENSMUSP00000096945; ENSMUSG00000005897. [Q505F1-1]
DR   Ensembl; ENSMUST00000105290; ENSMUSP00000100927; ENSMUSG00000005897. [Q505F1-1]
DR   GeneID; 22025; -.
DR   KEGG; mmu:22025; -.
DR   UCSC; uc007gvo.2; mouse. [Q505F1-1]
DR   CTD; 7181; -.
DR   MGI; MGI:1352465; Nr2c1.
DR   eggNOG; KOG3575; Eukaryota.
DR   GeneTree; ENSGT00940000158165; -.
DR   HOGENOM; CLU_007368_16_2_1; -.
DR   InParanoid; Q505F1; -.
DR   OMA; LVMEHIF; -.
DR   OrthoDB; 278171at2759; -.
DR   TreeFam; TF316650; -.
DR   Reactome; R-MMU-383280; Nuclear Receptor transcription pathway.
DR   BioGRID-ORCS; 22025; 0 hits in 52 CRISPR screens.
DR   ChiTaRS; Nr2c1; mouse.
DR   PRO; PR:Q505F1; -.
DR   Proteomes; UP000000589; Chromosome 10.
DR   RNAct; Q505F1; protein.
DR   Bgee; ENSMUSG00000005897; Expressed in retina and 273 other tissues.
DR   Genevisible; Q505F1; MM.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0004879; F:nuclear receptor activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:MGI.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0048856; P:anatomical structure development; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0048386; P:positive regulation of retinoic acid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Receptor; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..590
FT                   /note="Nuclear receptor subfamily 2 group C member 1"
FT                   /id="PRO_0000053587"
FT   DOMAIN          333..577
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        98..173
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         101..121
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         137..156
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..166
FT                   /note="Required for interaction with KAT2B"
FT   REGION          571..590
FT                   /note="Required for interaction with NRIP1"
FT   MOD_RES         185
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16317770"
FT   MOD_RES         203
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MOD_RES         208
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MOD_RES         210
FT                   /note="Phosphothreonine; by MAPK1"
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MOD_RES         461
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:16130175"
FT   MOD_RES         568
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:16130175"
FT   CROSSLNK        238
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:17187077"
FT   CROSSLNK        238
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P13056"
FT   CROSSLNK        575
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P13056"
FT   VAR_SEQ         220..256
FT                   /note="SAGLLDSGMFVNIHPSGIKTEPAMLMAPDKAESCQGD -> CPAAISASFAS
FT                   LPRSTETKTCASFVAGQLDCWIQECL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9071982"
FT                   /id="VSP_051921"
FT   VAR_SEQ         257..590
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9071982"
FT                   /id="VSP_051922"
FT   VARIANT         29
FT                   /note="I -> M (in strain: CD-1)"
FT                   /evidence="ECO:0000269|PubMed:8595902,
FT                   ECO:0000269|PubMed:8858600"
FT   VARIANT         145
FT                   /note="I -> M (in strain: CD-1)"
FT                   /evidence="ECO:0000269|PubMed:8595902,
FT                   ECO:0000269|PubMed:8858600"
FT   VARIANT         296..304
FT                   /note="FGAFHHDIQ -> SVLFIMIFK (in strain: CD-1)"
FT                   /evidence="ECO:0000269|PubMed:8595902,
FT                   ECO:0000269|PubMed:8858600"
FT   VARIANT         361
FT                   /note="V -> I (in strain: CD-1)"
FT                   /evidence="ECO:0000269|PubMed:8595902,
FT                   ECO:0000269|PubMed:8858600"
FT   VARIANT         377
FT                   /note="V -> A (in strain: CD-1)"
FT                   /evidence="ECO:0000269|PubMed:8595902,
FT                   ECO:0000269|PubMed:8858600"
FT   VARIANT         456
FT                   /note="P -> A (in strain: CD-1)"
FT                   /evidence="ECO:0000269|PubMed:8595902,
FT                   ECO:0000269|PubMed:8858600"
FT   MUTAGEN         167
FT                   /note="K->A: No effect on sumoylation."
FT                   /evidence="ECO:0000269|PubMed:17187077"
FT   MUTAGEN         170
FT                   /note="S->A: No effect on sumoylation nor on DNA-binding
FT                   and little effect on binding KAT2B. Greatly reduced DNA-
FT                   binding, binding to KAT2B and activation of the RARB
FT                   promoter; when associated with A-185."
FT                   /evidence="ECO:0000269|PubMed:16317770,
FT                   ECO:0000269|PubMed:18682553"
FT   MUTAGEN         185
FT                   /note="S->A: No effect on sumoylation and little effect on
FT                   binding KAT2B. Some reduced DNA-binding. Greatly reduced
FT                   DNA-binding, binding to KAT2B and activation of the RARB
FT                   promoter; when associated with A-170."
FT                   /evidence="ECO:0000269|PubMed:16317770,
FT                   ECO:0000269|PubMed:18682553"
FT   MUTAGEN         203
FT                   /note="S->A: No effect on sumoylation."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         208
FT                   /note="T->A: No effect on sumoylation."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         210
FT                   /note="T->A: Abolishes sumoylation. No repression of OCT4
FT                   gene expression with or without retinoic acid and enhanced
FT                   interaction with KAT2B and HDAC3. Abolishes interaction
FT                   with HDAC3 and PML association; when associated with R-
FT                   238."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         210
FT                   /note="T->E: Sumoylated. Repressed OCT4 gene expression.
FT                   Enhanced interaction with KAT2B; when associated with R-
FT                   238."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         238
FT                   /note="K->A: Abolishes sumoylation. Strongly associated
FT                   with PML nuclear bodies. No effect on activation of OCT4
FT                   but activation not suppressed by additional SUMO1.
FT                   Increased binding to KAT2B and reduced binding to NRIP1.
FT                   Abolishes PML association; when associated with A-210."
FT                   /evidence="ECO:0000269|PubMed:17187077,
FT                   ECO:0000269|PubMed:18682553"
FT   MUTAGEN         238
FT                   /note="K->R: Abolishes sumoylation. No effect on activation
FT                   of OCT4 but activation not suppressed by additional SUMO1.
FT                   Enhanced interaction with KAT2B; when associated with A-210
FT                   or E-210."
FT                   /evidence="ECO:0000269|PubMed:17187077,
FT                   ECO:0000269|PubMed:18682553"
FT   MUTAGEN         240
FT                   /note="E->A: Abolishes sumoylation."
FT                   /evidence="ECO:0000269|PubMed:17187077"
FT   MUTAGEN         461
FT                   /note="S->A: Little effect on PKC-stimulated protein
FT                   stability nor on activation of RARB reporter."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         461
FT                   /note="S->A: No effect on sumoylation."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         568
FT                   /note="S->A: Greatly reduced PKC-stimulated protein
FT                   stability and activation of RARB reporter."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         568
FT                   /note="S->A: No effect on sumoylation."
FT                   /evidence="ECO:0000269|PubMed:18682553"
FT   MUTAGEN         575
FT                   /note="K->R: No effect on sumoylation."
FT                   /evidence="ECO:0000269|PubMed:17187077"
FT   CONFLICT        88
FT                   /note="K -> N (in Ref. 4; CAA72244, 5; AAC29502 and 6;
FT                   AAL31315)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        200
FT                   /note="D -> N (in Ref. 5; AAC29502 and 6; AAL31315)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        273
FT                   /note="A -> T (in Ref. 5; AAC29502 and 6; AAL31315)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        326..327
FT                   /note="SA -> TS (in Ref. 1; AAC52787/AAC53253, 4; CAA72244
FT                   and 6; AAL31315)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        331
FT                   /note="P -> S (in Ref. 5; AAC29502 and 6; AAL31315)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        529
FT                   /note="D -> N (in Ref. 7; BAE27509)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   590 AA;  65476 MW;  E639AF3E5312918D CRC64;
     MATIEEIAHQ IIDQQMGEIV TEQQTGQKIQ IVTALDHSTQ GKQFILANHE GSTPGKVFLT
     TPDAAGVNQL FFTSPDLSAP HLQLLTEKSP DQGPNKVFDL CVVCGDKASG RHYGAITCEG
     CKGFFKRSIR KNLVYSCRGS KDCVINKHHR NRCQYCRLQR CIAFGMKQDS VQCERKPIEV
     SREKSSNCAA STEKIYIRKD LRSPLAATPT FVTDSETARS AGLLDSGMFV NIHPSGIKTE
     PAMLMAPDKA ESCQGDLSTL ASVVTSLANL GKAKDLSHCG GDMPVVQSLR NGDTSFGAFH
     HDIQTNGDVS RAFDTLAKAL TPGESSACQS PEEGMEGSPH LIAGEPSFVE KEGPLLSESH
     VAFRLTMPSP MPEYLNVHYI GESASRLLFL SMHWALSIPS FQALGQENSI SLVKAYWNEL
     FTLGLAQCWQ VMNVATILAT FVNCLHSSLQ QDKMSPERRK SLMEHIFKLQ EFCNSMVKLC
     IDGHEYAYLK AIVLFSPDHP GLENMELIER FQEKAYVEFQ DYITRTYPDD TYRLSRLLLR
     LPALRLMNAT ITEELFFKGL IGNVRIDSVI PHILKMEPAD YNSQIIGHSL
//
